Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes : A meta-analysis of pivotal trials

Publié dans Platelets 2017 Mar;28(2):174-181 Auteurs : Roule V, Agueznai M, Sabatier R, Blanchart K, Lemaitre A, Ardouin P, Collet JP, Milliez P, Montalescot G, Beygui F. Article disponible en consultant le site Abstract The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regimens in acute coronary syndromes (ACS) remain unassessed.…

Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention : An Analysis of the Randomized ATOLL Trial

Publié dans Angiology. 2017 Jan;68(1):29-39 Auteurs : Liu Z, Silvain J, Kerneis M, Barthélémy O, Payot L, Choussat R, Sabouret P, Cohen M, Pollack CV Jr, Goldstein P, Zeymer U, Huber K, Vicaut E, Collet JP, Montalescot G. Article disponible en consultant le site Abstract Elderly (≥75 years old) patients with ST-segment elevation myocardial infarction…

Anticoagulation in Coronary Intervention

Publié dans European Heart Journal 2016 Dec;37:3376–3385 Auteurs : Zeymer U, Rao SV, Montalescot G. Article disponible en consultant le site Abstract Percutaneous coronary intervention (PCI) induces thrombin generation and is associated with the risk of acute, subacute, or long-term ischaemic events. Therefore, intravenous anticoagulation is recommended to minimize thrombotic complications. The intensity and duration…